Recipharm Acquires Italian Injectables CDMO for $75 Million
By

Recipharm AB, a contract development and manufacturing organization (CDMO) headquartered in Jordbro, Sweden, has agreed to acquire the Italian CDMO, Mitim Srl for SEK 640 million ($75 million) Mitim is currently owned by a private Italian family and specializes in the filling of injectable beta lactam products. It is located in Brescia, Italy, close to Recipharm's existing operations in northern Italy. The transaction is expected to be completed on February 24, 2016.

Mitim’s product portfolio includes beta lactams in dry sterile powder for injectable solutions, tablets and oral suspensions. Other products include injectable sterile solutions, oral solids and liquids as well as semi-solids. The manufacturing site has five production lines and the company completed a t investment in a new production line for injectable beta lactams in March 2015. Mitim employs approximately 250 people.

Source: Recipharm

Leave a Reply

Your email address will not be published.